The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ARMP | +200% | +71.32% | +11.37% | +45% |
| S&P | +14.08% | +93.57% | +14.12% | +138% |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company was founded on May 9, 2019 and is headquartered in Los Angeles, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.17M | 0.0% |
| Gross Profit | $1.80M | 672.4% |
| Gross Margin | 83.13% | 0.0% |
| Market Cap | $68.77M | -30.8% |
| Market Cap / Employee | $1.15M | 0.0% |
| Employees | 60 | -9.1% |
| Net Income | -$16.30M | -281.3% |
| EBITDA | -$6.48M | 44.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $4.33M | -83.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $27.13M | -3.6% |
| Short Term Debt | $116.82M | -1.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.19% | 36.8% |
| Return On Invested Capital | -61.57% | 13.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.36M | 36.2% |
| Operating Free Cash Flow | -$7.21M | 29.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.86 | -1.31 | -1.10 | -1.28 | -27.28% |
| Price to Sales | 15.68 | 21.13 | 11.24 | 10.01 | -76.75% |
| Price to Tangible Book Value | -1.43 | -1.03 | -0.86 | -1.02 | -28.00% |
| Enterprise Value to EBITDA | -22.10 | -22.30 | -22.50 | -32.17 | 33.30% |
| Return on Equity | -3439.4% | - | |||
| Total Debt | $140.33M | $126.52M | $134.66M | $143.96M | -1.50% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
